Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its first pre-planned data review meeting and recommended the continuation of the Company’s trial without protocol amendment. In addition, and as previously indicated, no serious adverse events, liver-related adverse events or drop outs have been reported to date.

More information on :